Skin problems and EGFR-tyrosine kinase inhibitor

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) inhibitors are crucial in treating lung, colon, pancreatic, and head and neck cancers.
• EGFR-tyrosine kinase inhibitors (TKIs) were first approved for advanced lung cancer in 2002.
• EGFR inhibitors are particularly vital for patients with EGFR-activating mutations.

Purpose of the Study:

• To review the mechanisms of EGFR inhibitor-associated skin toxicities.
• To outline upfront preventive strategies for skin toxicities.
• To discuss reactive treatment options for managing EGFR inhibitor-induced skin adverse events.

Main Methods:

• Literature review of EGFR inhibitor mechanisms.
• Analysis of clinical data on skin toxicity management.
• Synthesis of information on preventive and reactive treatments.

Main Results:

• Skin toxicity is a significant and common side effect of EGFR inhibitor therapy.
• Understanding the mechanism of toxicity is key to effective management.
• A combination of preventive and reactive strategies can mitigate skin toxicity.

Conclusions:

• EGFR inhibitors are effective cancer treatments, but skin toxicity can impact patient quality of life and treatment adherence.
• Physicians need a thorough understanding of EGFR inhibitor-associated skin toxicities.
• Effective management strategies are available to address these dermatological side effects.